منابـــع و مراجــــع

1. http://www.roshd.ir/Default.aspx?tabid=442&EntryID=1681&SSOReturnPage=Check&Rand=0, 2012/7/4.

2. Peer, D., et al., Nanocarriers as an emerging platform for cancer therapy. Nat Nano, 2007. 2(12): p. 751-760.

3. Wu, G., et al., Chapter 14 Synthesis, Characterization, and Optical Response of Gold Nanoshells Used to Trigger Release from Liposomes, in Methods in Enzymology, D. Nejat, Editor. 2009, Academic Press. p. 279-307.

4. Anderson, L.J.E., et al., Optically guided controlled release from liposomes with tunable plasmonic nanobubbles. Journal of Controlled Release, 2010. 144(2): p. 151-158.

5. Liu, Z., et al., siRNA Delivery into Human T Cells and Primary Cells with Carbon-Nanotube Transporters. Angewandte Chemie International Edition, 2007. 46(12): p. 2023-2027.

6. Désormeaux, A. and M.G. Bergeron, Liposomes as Drug Delivery System: A Strategic Approach for the Treatment of HIV Infection. Journal of Drug Targeting, 1998. 6(1): p. 1-15.

7. Steger, L.D. and R.J. Desnick, Enzyme therapy VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1977. 464(3): p. 530-546.

8. Finkelstein, M. and G. Weissmann, The introduction of enzymes into cells by means of liposomes. J Lipid Res, 1978. 19(3): p. 289-303.

9. Kubo, T., et al., Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. International journal of oncology, 2000. 17(2): p. 309-315.

10. Minko, T., et al., New generation of liposomal drugs for cancer. Anti-cancer agents in medicinal chemistry, 2006. 6(6): p. 537-552.

11. Anaissie, E., et al., Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. European Journal of Clinical Microbiology & Infectious Diseases, 1991. 10(8): p. 665-668.

12. Date, A.A., M.D. Joshi, and V.B. Patravale, Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Advanced Drug Delivery Reviews, 2007. 59(6): p. 505-521.

13. Alving, C.R., Liposomes as drug carriers in leishmaniasis and malaria. Parasitology Today, 1986. 2(4): p. 101-107.

14. Alving, C.R., et al., Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs. Proceedings of the National Academy of Sciences, 1978. 75(6): p. 2959-2963.

15. Drulis-Kawa, Z. and A. Dorotkiewicz-Jach, Liposomes as delivery systems for antibiotics. International Journal of Pharmaceutics, 2010. 387(1–2): p. 187-198.

16. Kilian, G., et al., Antimicrobial activity of liposome encapsulated cyclo(L-tyrosyl-L-prolyl). Pharmazie, 2011. 66(6): p. 421-3.

17. Barani, H., et al., Synthesis of Ag-liposome nano composites. Journal of Liposome Research, 2010. 20(4): p. 323-329.

18. Malcher, M., et al., Embedded Silver Ions-Containing Liposomes in Polyelectrolyte Multilayers: Cargos Films for Antibacterial Agents. Langmuir, 2008. 24(18): p. 10209-10215.

19. Li, C.Q., et al., Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol, 2005. 11(3): p. 426-8.

20. Gilbert, B.E. and V. Knight, Pulmonary delivery of antiviral drugs in liposome aerosols. Seminars in Pediatric Infectious Diseases, 1996. 7(2): p. 148-154.

21. Koff, W.C. and I.J. Fidler, The potential use of liposome-mediated antiviral therapy. Antiviral Research, 1985. 5(3): p. 179-190.

22. Pollock, S., et al., N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS, 2008. 22(15).

23. Logue, C.H., et al., Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge. Antiviral Res, 2010. 87(2): p. 195-203.

24. Mannino, R.J. and S. Gould-Fogerite, Liposome mediated gene transfer. BioTechniques, 1988. 6(7): p. 682-690.

25. Straubinger, R.M. and D. Papahadjopoulos, [32] Liposomes as carriers for intracellular delivery of nucleic acids, in Methods in Enzymology, L.G.K.M. Ray Wu, Editor. 1983, Academic Press. p. 512-527.

26. Nicolau, C., A. Legrand, and E. Grosse, [16] Liposomes as carriers for in vivo gene transfer and expression, in Methods in Enzymology, K.J.W. Ralph Green, Editor. 1987, Academic Press. p. 157-176.

27. Madeira, C., et al., Nonviral Gene Delivery to Mesenchymal Stem Cells Using Cationic Liposomes for Gene and Cell Therapy. Journal of Biomedicine and Biotechnology, 2010. 2010.

28. Lee, E.M., et al., Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J Cancer Res Clin Oncol, 2004. 130(3): p. 169-77.

29. Fujii, Y., et al., Transfer of gene to human retinal pigment epithelial cells using magnetite cationic liposomes. British Journal of Ophthalmology, 2010. 94(8): p. 1074-1077.

30. Malone, R.W., P.L. Felgner, and I.M. Verma, Cationic liposome-mediated RNA transfection. Proceedings of the National Academy of Sciences, 1989. 86(16): p. 6077-6081.

31. Kinet, V., et al., Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Letters, 2009. 284(2): p. 222-228.

32. Williams, L.E., R.T. Proffitt, and L. Lovisatti, Possible applications of phospholipid vesicles (liposomes) in diagnostic radiology. J Nucl Med Allied Sci, 1984. 28(1): p. 35-45.

33. Presant, C.A., et al., Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. Cancer, 1988. 62(5): p. 905-911.

34. Dong, L., et al., Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine, 2012. 30(2): p. 254-264.

35. Bernstein, D.I., et al., Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines. Clinical and Vaccine Immunology, 2009. 16(5): p. 699-705.

36. Christensen, D., et al., Liposome-based cationic adjuvant formulations (CAF): Past, present, and future. Journal of Liposome Research, 2009. 19(1): p. 2-11.

37. Tiwari, S., et al., Liposome in situ gelling system: Novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine. Procedia in Vaccinology, 2009. 1(1): p. 148-163.

38. Christensen, D., et al., Cationic liposomes as vaccine adjuvants. Expert Review of Vaccines, 2011. 10(4): p. 513-521.

39. Niesman, M.R., The use of liposomes as drug carriers in ophthalmology. Critical reviews in therapeutic drug carrier systems, 1992. 9(1): p. 1-38.

40. Singh, K. and M. Mezei, Liposomal ophthalmic drug delivery system. II. Dihydrostreptomycin sulfate. International Journal of Pharmaceutics, 1984. 19(3): p. 263-269.

41. Singh, K. and M. Mezei, Liposomal ophthalmic drug delivery system I. Triamcinolone acetonide. International Journal of Pharmaceutics, 1983. 16(3): p. 339-344.

42. Ebrahim, S., G.A. Peyman, and P.J. Lee, Applications of Liposomes in Ophthalmology. Survey of Ophthalmology, 2005. 50(2): p. 167-182.

43. Zhang, L., et al., Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther, 2007. 83(5): p. 761-769.

44. Süleymanoglu, E., A NANOSCALE POLYNUCLEOTIDE-NEUTRAL LIPOSOME SELF-ASSEMBLIES FORMULATED FOR THERAPEUTIC GENE DELIVERY. Rev Electron Biomed / Electron J Biomed 2004(2): p. 13-35.